Tagged with GE

Saudi Arabia Ali Yehia, Country Manager for Viatris KSA, speaks about the company’s global operations and its plans for KSA, notably to play an active role in the fight against non-communicable diseases. He tackles the evolving healthcare landscape and the opportunity for the country to expand its regional role.   Viatris was…

Global David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal activities and financings over the past two years since his original article on the topic was published on PharmaBoardroom in June 2019.   Cell and gene…

Global PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca and the EU, the skills that pharma leaders need in the MEA region, the year’s most prominent trends, and how…

Saudi Arabia Amr Seif introduces the evolution in Astellas’ MEA strategy; the adoption of innovative access models to ensure that the companies’ therapies are available for all patients who need them; and the challenges and opportunities in the Saudi pharma market.   We are opening a new chapter in medicine. The early…

Saudi Arabia Emcure’s Senior VP for the Middle East, North & West Africa, Afghanistan, Pakistan & Turkey, Amr El-Neklawy, highlights the level of organizational independence given to his region, the necessity of agility and focus when competing in the generics market, and how the Indian multinational is standing out by offering its…

Global PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work has taken on in the past 12 months. From one of Asia’s leading regulatory bodies to some of the Middle East’s most dynamic emerging companies via…

Global Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more.   1. United States Way out in first place with a market value of USD 533.5 billion in sales in 2020,…

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

China The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention than ever before. Suzhou, China-based biotech Abogen, for example, which has an mRNA-based COVID vaccine in late-stage development, has received…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Global Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate, short- medium-, and long-term. This piece forms part of our special section, InFocus: Patient Engagaement in the Era of CAR-T.…

Saudi Arabia Few stakeholders are better placed to assess the landscape for rare disease therapies across the Middle East and North Africa (MENA) region than Karim Smaira and Kamel Ghammachi of Genpharm, an entrepreneurial success story that now provides market access and marketing solutions for rare disease products across the region.  …